Torsdag 25 Juni | 17:33:41 Europe / Stockholm
Est. tid*
2027-03-04 19:30 Bokslutskommuniké 2026
2026-08-27 19:30 Kvartalsrapport 2026-Q2
2026-06-26 N/A X-dag ordinarie utdelning 2CUREX 0.00 SEK
2026-06-25 N/A Årsstämma
2026-02-26 - Bokslutskommuniké 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-06-27 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2025-06-26 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-12-18 - Extra Bolagsstämma 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 - Årsstämma
2024-02-22 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-11-14 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Kvartalsrapport 2023-Q1
2023-05-26 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 - Årsstämma
2023-02-23 - Bokslutskommuniké 2022
2023-02-10 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 - Årsstämma
2021-05-27 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-07-02 - Extra Bolagsstämma 2020
2020-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 - Årsstämma
2020-05-28 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 - Årsstämma
2019-05-17 - Kvartalsrapport 2019-Q1
2019-04-02 - Extra Bolagsstämma 2019
2019-03-01 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 - Årsstämma
2018-05-18 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamt inom cancerbehandling. Bolaget tillhandahåller olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Communiqué from the Annual General Meeting on Thursday 25 June 2026 in 2cureX AB

2026-06-25 15:00:00

N.B. The English text is an unofficial translation. Today, 25 June 2026, the Annual General Meeting (the “AGM”) of 2cureX AB, reg. no. 559128-0077, was held. Below is a summary of the resolutions passed. All resolutions were passed with the required majority.

Communiqué from the Annual General Meeting on Thursday 25 June 2026 in 2cureX AB

Today, 25 June 2026, the Annual General Meeting (the “AGM”) of 2cureX AB, reg. no. 559128-0077, was held. Below is a summary of the resolutions passed. All resolutions were passed with the required majority.

Adoption of the income statement and balance sheet (Item 8a)
The AGM resolved to adopt the presented income statement and balance sheet.

Resolution regarding appropriation of the company's profit according to the adopted balance sheet (Item 8b)
The AGM resolved to dispose of the company's profit in accordance with the Board's proposal in the annual report. The AGM resolved that no dividend will be paid for the financial year 2025.

Discharge from liability of the members of the Board of Directors and the CEO (Item 8c)
The AGM resolved to discharge the members of the Board of Directors and the CEO from liability for the financial year 2025.

Determination of the number of Board members and the number of auditors (Item 9)
The AGM resolved that the number of Board members shall amount to five (5). The AGM resolved that one (1) auditor shall be appointed.

Determination of fees for the Board of Directors and the auditor (Item 10)
The AGM resolved that Board fees shall be paid in the amount of SEK 300,000 to the Chairman of the Board and SEK 150,000 to each of the other Board members. Furthermore, the AGM resolved that fees to the auditor shall be paid in accordance with approved invoices in accordance with customary billing standards.

Election of the Board of Directors and auditor (Item 11)
The AGM resolved to re-elect Ole Thastrup, Grith Hagel and Nathaniel Hutley and to newly elect Malgorzata Khrais and Jacob Scott as ordinary Board members. Ole Thastrup was re-elected as Chairman of the Board. Tonni Bülow-Nielsen had declined re-election. Furthermore, the AGM resolved to re-elect Martin Gustafsson as the company's auditor until the end of the Annual General Meeting to be held next financial year.

Resolution on amendment of the Articles of Association (Item 12)
The AGM resolved, in accordance with the Board's proposal, to amend the Articles of Association so that the limits for the share capital are changed to not less than SEK 3,190,291.60 and not more than SEK 12,761,166.40, and the limits for the number of shares are changed to not less than 31,902,916 and not more than 127,611,664.

Resolution authorising the Board of Directors to resolve on share issues (Item 13)
The AGM resolved, in accordance with the Board's proposal, to authorise the Board of Directors, during the period until the next Annual General Meeting, to resolve on the issue of a maximum number of shares, convertibles and/or warrants that entitle to subscription of, or entail the issue of, a maximum number of shares that fit within the limits of the Articles of Association, with or without deviation from shareholders' preferential rights. The authorisation may be exercised on one or more occasions and the Board of Directors shall have the right to decide on the detailed issue terms on each individual occasion. In addition to cash payment, payment may also be made with consideration in kind or by set-off, or otherwise with conditions.

In order for the company's current shareholders not to be disadvantaged in relation to the external investor or investors who may subscribe for shares in the company, the Board of Directors considers it appropriate that an issue with deviation from the shareholders' preferential rights shall be made at the Board's market-based subscription price, subject to a market-based issue discount where applicable.

Malmö, June 2026

2cureX AB

THE BOARD OF DIRECTORS